

EKF Diagnostics Holdings plc
("EKF" or the "Company")

**Posting of Annual Report & Accounts
And
Notice of AGM**

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, confirms that the Annual Report and Accounts for the year ended 31 December 2022 ("2022 Annual Report") and the Notice of the 2023 Annual General Meeting ("AGM") have now been published on the Company's website:

<https://www.ekfdiagnostics.com/documents-reports.html>

The 2022 Annual Report, the Notice of AGM and details for voting by proxy will be posted today to shareholders who have not consented to receive electronic communications.

The AGM is to be held at 10:30 am on 17 May 2023 at 6 Stratton Street Mayfair, London W1J 8LD and will consider the Resolutions set out in the Notice of AGM.

The Company is providing a facility for shareholders to listen in to the AGM either online or telephonically (in a non-voting capacity) and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Directors would request that shareholders register for the meeting and submit questions in advance, before 10:30 am on 15 May 2023. To register for dial-in details and to submit any questions please contact Walbrook PR via email at ekf@walbrookpr.com or call +44 (0)20 7933 8780.

Proxy voting

Shareholders will not receive a hard copy form of proxy for the 2023 AGM in the post. Instead, shareholders will be able to vote electronically using the link available via <https://www.signalshares.com> and selecting the "Proxy Voting" link or lodging a proxy appointment by using the CREST Proxy Voting Service.

Alternatively, shareholders may request a hard copy form of proxy directly from the Registrars, Link Group, on Tel: 0371 664 0391. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales.

EKF Diagnostics Holdings plc

Julian Baines, Executive Chair / Marc Davies, CFO

www.ekfdiagnostics.com

Tel: +44 (0)29 2071 0570

Singer Capital Markets (Nominated Adviser & Broker)

Aubrey Powell / George Tzimas / Oliver Platts

Tel: +44 (0)20 7496 3000

Walbrook PR Limited

Paul McManus / Lianne Applegarth

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes, as well as **Central Laboratory** products including clinical chemistry reagents, analysers and centrifuges
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications, as well as other higher value **Contract Manufacturing** services

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCIBMJTMTTBIJ Anonymous (not verified) Posting of Annual Report & Notice of AGM 33452464
A Fri, 04/21/2023 - 14:30 LSE RNS Company Announcement - General EKF